Avasimibe is a medication belonging to the class of drugs known as ACAT inhibitors, which are used in the treatment of atherosclerosis, hyperlipidemia, and other related disorders. This drug is primarily utilized as a research tool in animal studies and has not been approved for clinical use in humans. Avasimibe CAS: 166518-60-1 is a small molecule inhibitor of the Acyl-CoA: cholesterol acyltransferase (ACAT) enzyme, which is involved in the synthesis and storage of cholesterol esters in the body.
Chemical name: (3aS,4R,6aR)-4-{4-[(4-fluorophenyl)phenylmethyl]piperidin-1-yl}-2-methyl-2,3,3a,4,5,6,6a-heptahydro-1H-benzo[de]isoquinoline-1,3-dione Molecular formula: C32H33FN2O3 Formula weight: 514.62 g/mol CAS No: 166518-60-1
Top ten keywords from Google:
Synonyms: CI-1011; PD 189659.
Health benefits of Avasimibe: Avasimibe is a research tool primarily used in animal studies to investigate the role of the ACAT enzyme in the formation and storage of cholesterol esters in the body. The drug is not approved for clinical use in humans, and thus there is no established health benefit associated with its use.
Potential effects: Avasimibe works by inhibiting the activity of the ACAT enzyme, which is responsible for the conversion of cholesterol into cholesterol esters. By blocking this enzyme, Avasimibe can reduce the formation and storage of cholesterol esters in the body, which can help reduce the risk of atherosclerosis and other related disorders.
Product mechanism: The ACAT enzyme is responsible for catalyzing the conversion of free cholesterol to cholesterol esters, which are then stored in lipid droplets within cells. Avasimibe works by inhibiting the activity of this enzyme, leading to reduced cholesterol esterification and storage in the body. This mechanism of action has been shown to have potential therapeutic benefits in the treatment of atherosclerosis and hyperlipidemia.
Safety: Since Avasimibe is not approved for clinical use in humans, there is limited information available regarding its safety profile. However, preclinical studies have shown that the drug may cause gastrointestinal disturbances, such as diarrhea and nausea.
Side effects: The most common side effects reported in preclinical studies of Avasimibe include gastrointestinal disturbances, such as diarrhea and nausea. The drug may also cause liver toxicity and other adverse effects, although these have not been extensively studied in humans.
Dosing information: Since Avasimibe is not approved for clinical use in humans, there is no established dosing information available. However, preclinical studies have shown that the drug is most effective at doses ranging from 5 to 20 mg/kg.
Conclusion: Avasimibe is a small molecule inhibitor of the ACAT enzyme, which is involved in the synthesis and storage of cholesterol esters in the body. The drug has potential therapeutic benefits in the treatment of atherosclerosis, hyperlipidemia, and other related disorders. However, since the drug has not been approved for clinical use in humans, its safety and efficacy are yet to be established. Researchers continue to investigate the potential benefits of Avasimibe in clinical trials and preclinical studies to determine whether the drug may be useful in the treatment of various metabolic disorders.
